Batten Disease Clinical Trial
Official title:
Administration of a Replication Deficient Adeno-associated Virus Gene Transfer Vector Expressing the Human CLN2 cDNA to the Brain of Children With Late Infantile Neuronal Ceroid Lipofuscinosis
The aim of this study is to treat the signs and symptoms of late infantile neuronal ceroid lipofuscinosis (LINCL), a fatal inherited disease in the brain. This will be accomplished by using delivery of a gene (method called gene transfer) to administer to the brain an experimental drug called AAV2CUhCLN2, a gene transfer vector.
Late infantile neuronal ceroid lipofuscinosis (LINCL) is a fatal childhood neurodegenerative
lysosomal storage disease with no known therapy. There are estimated to be 200 to 300
children in the USA at any one time with the disease. LINCL is a genetic disease resulting
from mutations in the CLN2 gene. The CLN2 gene encodes a protein tripeptidyl peptidase-I
(TPP-I) which is absent/deficient in children with LINCL. This absence/deficiency of TPP-I
results in lysosomal storage and subsequent cell death (especially neurons). The children
with LINCL are chronically ill, with a progressive CNS disorder that invariably results in
death, typically by age 8 to 12.
This clinical study will evaluate the concept that persistent expression of the normal CLN2
cDNA in the CNS will result in the production of sufficient amounts of TPP-I to prevent
further loss of neurons, and hence limit disease progression. To assess this concept, an
adeno-associated virus vector encoding the normal human CLN2 gene (AAV2CUhCLN2) will be used
as a vehicle to deliver and express the human CLN2 cDNA in the brain of children with LINCL.
The proposed study will include 11 individuals and will be divided into two parts. Group A,
to be studied first, will include 5 individuals with the severe form of the disease. Group B
of the trial will include 6 individuals with a moderate form of the disease. Following direct
intracranial administration of the vector, there will be neurological assessment using the
LINCL clinical rating scale and magnetic resonance imaging/magnetic resonance spectroscopy
assessment of the CNS in regions of vector administration. The data generated will help
evaluate two hypotheses: (1) that it is safe to carry out direct intracranial administration
of the AAV2CUhCLN2 vector to the CNS of individuals with LINCL; and (2) that administration
of the AAV2CUhCLN2 vector will slow down or halt the progression of the disease in the
central nervous system.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT02254863 -
UCB Transplant of Inherited Metabolic Diseases With Administration of Intrathecal UCB Derived Oligodendrocyte-Like Cells
|
Phase 1 | |
Completed |
NCT01907087 -
A Phase 1/2 Open-Label Dose-Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of Intracerebroventricular BMN 190 in Patients With Late-Infantile Neuronal Ceroid Lipofuscinosis (CLN2) Disease
|
Phase 1/Phase 2 | |
Recruiting |
NCT03307304 -
Investigations of Juvenile Neuronal Ceroid Lipofuscinosis
|
||
Active, not recruiting |
NCT03770572 -
Gene Therapy for Children With CLN3 Batten Disease
|
Phase 1/Phase 2 | |
Recruiting |
NCT06203106 -
NYSCF Scientific Discovery Biobank
|
||
Completed |
NCT00151268 -
Genotype - Phenotype Correlations of LINCL
|
N/A | |
Recruiting |
NCT02435940 -
Inherited Retinal Degenerative Disease Registry
|
||
Completed |
NCT01035424 -
Genotype-Phenotype Correlations of Late Infantile Neuronal Ceroid Lipofuscinosis
|
||
Active, not recruiting |
NCT04273243 -
Long-Term Follow Up of CLN6 Batten Disease Subjects Following Gene Transfer
|
||
Recruiting |
NCT03285425 -
Natural History of Neuronal Ceroid Lipofuscinosis, Batten's CLN6 Diseae
|
||
Completed |
NCT00176904 -
Stem Cell Transplant for Inborn Errors of Metabolism
|
Phase 2/Phase 3 | |
Recruiting |
NCT03333200 -
Longitudinal Study of Neurodegenerative Disorders
|
||
Completed |
NCT02678689 -
A Safety, Tolerability, and Efficacy Study of Intracerebroventricular BMN 190 in Pediatric Patients < 18 Years of Age With CLN2 Disease
|
Phase 2 | |
Completed |
NCT02485899 -
An Extension Study to Evaluate the Long-Term Efficacy and Safety of BMN 190 in Patients With CLN2 Disease
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT05174039 -
An Open-label Safety, Pharmacokinetic, and Efficacy Study of Miglustat for the Treatment of CLN3 Disease
|
Phase 1/Phase 2 | |
Terminated |
NCT01698229 -
Collection of Cerebrospinal Fluid in Healthy Children
|
N/A | |
Enrolling by invitation |
NCT03862274 -
Examining Developmental Outcomes of Children Diagnosed With CLN2 Disease
|
||
Recruiting |
NCT01873924 -
Clinical and Neuropsychological Investigations in Batten Disease
|
||
Completed |
NCT01161576 -
Safety Study of a Gene Transfer Vector (Rh.10) for Children With Late Infantile Neuronal Ceroid Lipofuscinosis (LINCL)
|
Phase 1 | |
Recruiting |
NCT04613089 -
Natural History and Longitudinal Clinical Assessments in NCL / Batten Disease, the International DEM-CHILD Database
|